MARKET

SRRK

SRRK

Scholar Rock Holding
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.72
-0.42
-2.97%
After Hours: 13.72 0 0.00% 16:09 10/26 EDT
OPEN
13.95
PREV CLOSE
14.14
HIGH
14.22
LOW
13.31
VOLUME
71.33K
TURNOVER
--
52 WEEK HIGH
21.92
52 WEEK LOW
6.95
MARKET CAP
409.88M
P/E (TTM)
-6.3109
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Scholar Rock Secures $50 million Debt Facility with Silicon Valley Bank and Oxford Finance
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the closing of a $50 million debt facility with Silicon Valley Bank and Oxford Finance LLC, of which the first $25 million was funded at closing. Scholar Rock intends to use the proceeds for general corporate purposes, including the advancement of the Company’s pipeline and for pre-commercialization preparations.
Business Wire · 10/19 12:30
Scholar Rock secures $50M debt facility for advancing pipeline
Scholar Rock (SRRK) closed a $50M debt facility with Silicon Valley Bank and Oxford Finance; first $25Mwas funded at closing.Proceeds to be used for general corporate purposes, including the advancement
Seekingalpha · 10/19 11:47
Scholar Rock Presents Data for SRK-015 at the World Muscle Society 2020 Virtual Congress
Scholar Rock Presents Data for SRK-015 at the World Muscle Society 2020 Virtual Congress
Business Wire · 09/30 12:30
Scholar Rock To Present Data For SRK-015 At The World Muscle Society 2020 Virtual Congress Oct. 1
Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced two poster presentations
Benzinga · 09/30 11:36
Roche and PTC's risdiplam shows durable effect in infants with spinal muscular atrophy
PTC Therapeutics (PTCT) and exclusive licensee Genentech, a unit of Roche (RHHBY), announce two-year data from Part 1 of the pivotal Phase 2/3 FIREFISH study evaluating Evrysdi (risdiplam) in infants
Seekingalpha · 09/28 10:44
Scholar Rock (SRRK) Presents At Morgan Stanley 18th Annual Global Healthcare Conference - Slideshow
The following slide deck was published by Scholar Rock Holding Corporation in conjunction with this event.
Seekingalpha · 09/17 23:21
Dosing is underway in early-stage study for Scholar Rock's SRK-181 in solid tumors
Scholar Rock (SRRK) has dosed the first patient with SRK-181 in combination with anti-PD-(L)1 therapy, in Part A2 of the DRAGON Phase 1 trial that consists of two parts, A and B, to evaluate
Seekingalpha · 09/09 12:44
Scholar Rock Announces First Patient Dosed In Part A2 Of DRAGON Phase 1 Proof-Of-Concept Trial Of SRK-181 To Overcome Primary Resistance To Anti-PD-(L)1 Therapy
- Patients with locally advanced or metastatic solid tumors are being enrolled and dosed with SRK-181 in combination with anti-PD-(L)1 therapy in Part A2 of the DRAGON Phase 1 clinical trial - An update on Part A
Patients with locally advanced or metastatic solid tumors are being enrolled and dosed with SRK-181 in combination with anti-PD-(L)1 therapy in Part A2 of the DRAGON Phase 1 clinical trial - An update on Part A · 09/09 11:36
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SRRK. Analyze the recent business situations of Scholar Rock Holding through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SRRK stock price target is 28.25 with a high estimate of 35.00 and a low estimate of 22.00.
EPS
Institutional Holdings
Institutions: 88
Institutional Holdings: 21.74M
% Owned: 72.77%
Shares Outstanding: 29.87M
TypeInstitutionsShares
Increased
36
1.39M
New
19
-88.13K
Decreased
13
350.09K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.74%
Pharmaceuticals & Medical Research
-0.94%
Key Executives
Chairman/Independent Director
David Hallal
President/Chief Executive Officer/Director
Tony Kingsley
Chief Financial Officer
Edward Myles
Senior Vice President - Finance
Erin Moore
Chief Scientific Officer
Alan Buckler
Other
Yung Chyung
Independent Director
Kristina Burow
Independent Director
Michael Gilman
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SRRK
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is engaged in the development of monoclonal antibodies for treatment of diseases, such as neuromuscular disorders, cancer, fibrosis, and anemia. The Company's lead product candidate is SRK-015 that is in its pre-clinical stage of development. SRK-015 is a selective inhibitor of the activation of the growth factor myostatin in skeletal muscle. It is used to treat spinal muscular atrophy (SMA). The Company also develops other antibody programs that include TGFβ1 and BMP6. The TGFβ1 antibody program is focused on the development of antibodies that are specific inhibitors of TGFβ1 members.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Scholar Rock Holding Corp stock information, including NASDAQ:SRRK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRRK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRRK stock methods without spending real money on the virtual paper trading platform.